FORTUNE 500

• Revenues, Profits
• Profits as % of...
• EPS, Total return, Employees
•  

			REVENUES		PROFITS
Rank	Company	Fortune 1000 rank	$ millions	% change from 2006	$ millions	% change from 2006
1	Johnson & Johnson	35	61,095.0	14.6	10,576.0	-4.3
2	Pfizer	47	48,418.0	-7.6	8,144.0	-57.9
3	Abbott Laboratories	96	25,914.2	15.3	3,606.3	110.1
4	Merck	101	24,197.7	6.9	3,275.4	-26.1
5	Wyeth	113	22,399.8	10.1	4,616.0	10.0
6	Bristol-Myers Squibb	125	19,977.0	11.5	2,165.0	36.6
7	Eli Lilly	133	18,633.5	18.8	2,953.0	10.9
8	Amgen	173	14,771.0	3.5	3,166.0	7.3
9	Schering-Plough	212	12,690.0	19.8	-1,473.0	-228.9
10	Gilead Sciences	536	4,230.0	39.8	1,615.3	0.0
11	Allergan	554	3,958.9	29.2	499.3	0.0
12	Genzyme	572	3,813.5	19.7	480.2	0.0
13	Forest Laboratories	605	3,441.8	16.2	454.1	-35.9
14	Hospira	608	3,436.2	27.8	136.8	-42.5
15	Biogen Idec	648	3,171.6	18.2	638.2	193.4
16	Mylan	736	2,666.0	65.4	-1,225.3	-663.9
17	Barr Pharmaceuticals	760	2,557.6	94.6	128.4	-61.9
18	Watson Pharmaceuticals	775	2,496.7	26.1	141.0	0.0
19	King Pharmaceuticals	857	2,136.5	7.4	183.0	-36.7
20	NBTY	894	2,014.5	7.1	207.9	86.0
21	Cephalon	952	1,772.6	0.5	-191.7	-232.4

Rank	Company	Revenues %	Assets %	Stockholders' Equity %
1	Johnson & Johnson	17.3	13.1	24.4
2	Pfizer	16.8	7.1	12.5
3	Abbott Laboratories	13.9	9.1	20.3
4	Merck	13.5	6.8	18.0
5	Wyeth	20.6	10.8	25.3
6	Bristol-Myers Squibb	10.8	8.3	20.5
7	Eli Lilly	15.8	11.0	21.6
8	Amgen	21.4	9.1	17.7
9	Schering-Plough	-11.6	-5.1	-14.2
10	Gilead Sciences	38.2	27.7	46.7
11	Allergan	12.6	7.6	13.4
12	Genzyme	12.6	5.8	7.3
13	Forest Laboratories	13.2	12.4	15.0
14	Hospira	4.0	2.7	7.8
15	Biogen Idec	20.1	7.4	11.5
16	Mylan	-46.0	-10.8	-36.0
17	Barr Pharmaceuticals	5.0	2.7	6.9
18	Watson Pharmaceuticals	5.6	4.1	7.6
19	King Pharmaceuticals	8.6	5.3	7.3
20	NBTY	10.3	13.5	19.7
21	Cephalon	-10.8	-5.5	-14.7

		EARNINGS PER SHARE	TOTAL RETURN TO INVESTORS		EMPLOYEES
Rank	Company	1997-2007 Annual growth (%)	1997-2007 Annual rate (%)	2007 (%)	Number	% change from 2006
1	Johnson & Johnson	11.7	9.2	3.7	119,200	-2.5
2	Pfizer	7.5	1.2	-8.1	86,600	-11.6
3	Abbott Laboratories	5.6	8.4	18.0	68,697	3.1
4	Merck	-2.2	4.3	37.6	58,900	-1.8
5	Wyeth	8.1	3.5	-11.4	50,527	0.9
6	Bristol-Myers Squibb	-3.6	-2.1	4.7	42,000	-2.3
7	Eli Lilly	0.0	-0.6	5.7	40,600	-2.2
8	Amgen	17.0	13.1	-32.0	17,450	-13.0
9	Schering-Plough	0.0	0.0	13.7	55,000	64.2
10	Gilead Sciences	0.0	34.4	41.7	2,941	16.9
11	Allergan	12.8	23.7	7.7	7,886	16.5
12	Genzyme	13.5	18.7	20.9	10,000	11.1
13	Forest Laboratories	0.0	19.4	-28.0	5,126	1.5
14	Hospira	0.0	0.0	27.0	14,000	7.7
15	Biogen Idec	0.0	25.8	15.7	4,300	14.7
16	Mylan	0.0	5.0	-28.9	12,000	87.5
17	Barr Pharmaceuticals	16.7	18.0	5.9	8,900	336.3
18	Watson Pharmaceuticals	2.3	-1.8	4.3	5,640	-3.3
19	King Pharmaceuticals	0.0	0.0	-35.7	2,051	-26.8
20	NBTY	26.5	9.4	-34.1	10,800	-0.9
21	Cephalon	0.0	20.2	1.9	2,796	-3.4